证券代码：688161 证券简称：威高骨科 山东威高骨科材料股份有限公司 2026 年第一次临时股东会 会议资料 二零二六年三月 山东威高骨科材料股份有限公司 2026 年第一次临时股东会会议资料 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证 会议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《山东威高骨科材料股份有限公司章程》等相关规定，山东威高骨科材料股份 有限公司（以下简称"公司"）特制定 2026 年第一次临时股东会会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议人员的身份进行必要的核对工作，请被核对者给予配合。 出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理签到 手续，并请按规定出示股票账户卡、身份证明文件或法人单位证明、授权委托 书等，经验证后领取会议资料，方可出席会议。 经公司审核，符合条件参加本次会议的股东、股东代理人、公司董事、高 级管理人员、聘任律师及董事会邀请的人员等可进入会场，公司有权拒绝不符 合条件的人员进入会场。 会议开始后，由会议主持人 ...

- The report introduces a comprehensive impact coefficient model to measure the influence of index rebalancing on individual stocks, particularly focusing on the March 2026 adjustments for key indices such as STAR 50, STAR-ChiNext 50, STAR 100, Dividend Low Volatility 100, and Beijing Stock Exchange 50[9][11][14] - The comprehensive impact coefficient is defined as follows: $ effect\_total_{s}=\sum_{i=1}^{n}\frac{wt\_chg_{s_{i}}\times fund\_size_{i}}{amount\_avg_{s_{i}}20} $ where: - $ wt\_chg_{s_{i}} $ represents the weight change of stock $ s $ in index $ i $ - $ fund\_size_{i} $ is the tracking scale of index $ i $ - $ amount\_avg_{s_{i}}20 $ is the average trading volume of stock $ s $ over the past 20 days[11] - The model evaluates the impact of passive trading caused by index rebalancing, emphasizing that larger indices with higher tracking scales (e.g., STAR 50 with 1489 billion RMB) generate more significant passive trading effects, creating potential investment opportunities for stocks added to these indices[13][14] - The report provides detailed calculations of the comprehensive impact coefficients for stocks with significant adjustments, identifying stocks like Jikang Technology (impact coefficient: 5.95), Zhongke Feice (impact coefficient: 1.73), and Taoli Bread (impact coefficient: 1.55) as having notable positive impacts due to their inclusion in indices such as Beijing Stock Exchange 50 and STAR 50[14][17] - Stocks removed from indices also exhibit negative impact coefficients, such as Weida Optoelectronics (-2.95), Jike Shares (-2.65), and Junshi Biosciences (-1.73), reflecting the adverse effects of exclusion from key indices[17]

【兴证医药】威高骨科2025年度业绩快报点评 单Q4，公司预计实现营业收入4.33亿元，同比增 单Q4，公司预计实现营业收入4.33亿元，同比增长17.2%；归母净利润0.59亿元，同比基本持平。 影响经营业绩的主要原因： （1）骨科带量采购执行平稳，国产头部品牌份额持续提升。 【兴证医药】威高骨科2025年度业绩快报点评 2025年，公司预计实现营业收入15.39亿元，同比增长5.95%；归母净利润2.67亿元，同比增长19.17%；扣非归母净 利润2.52亿元，同比增长19.59%。 若剔除股份支付费用影响，归母净利润约2.96亿元，同比增长约32.13%；扣非归母净利润约2.81亿元，同比增长约 33.34%。 2025年，公司预计实现营业收入15.39亿元，同比增长5.95%；归母净利润2.67亿元，同比增长19.17%；扣非归母净 利润2.52亿元，同比增长19.59%。 若剔除股份支付费用影响，归母净利润约2.96亿元，同比增长约32.13%；扣非归母净利润约2.81亿元，同比增长约 33.34%。 公司推进销售模式与组织架构调整，实施事业部利润中心制，提升销售专业性与市场覆盖；通过聚焦核心术式及 ...

证券代码：688161 证券简称：威高骨科 公告编号：2026-005 山东威高骨科材料股份有限公司2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载山东威高骨科材料股份有限公司（以下简称"公司"）2025年度主要财务数据为初步核算数 据，未经会计师事务所审计，具体数据以公司2025年年度的定期报告为准，提请投资者注意投资风险。 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度的定期报告为 准。 3.数据若有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期内公司的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况 报告期内，公司营业收入153,919.23万元，较上年同期增长5.95%；实现归属于母公司所有者的净利润 26,663.92万元，较上年同期增长19.17 %；实现归属于母公司所有者的扣除非经常性损益的净利润 25,218.28万元，同比增长19.59%。报告期内，公司实施2 ...

Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase compared to the previous year [1] Group 1: Financial Performance - The company achieved a revenue of 1.539 billion RMB, representing a 5.95% year-on-year increase [1] - The net profit attributable to the parent company's shareholders was 267 million RMB, showing a growth of 19.17% year-on-year [1] - Basic earnings per share were reported at 0.67 RMB [1] Group 2: Sales and Market Strategy - The overall execution of orthopedic bulk procurement remained stable during the reporting period, with leading domestic brands increasing their market share [1] - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around specialized departments [1] - There is a focus on product line segmentation and enhanced management through sales divisions, improving the professional capabilities and focus of the sales team [1] - The company is emphasizing collaborative sales across key surgical procedures, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [1]

Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase compared to the previous year [1][1][1] Financial Performance - The company achieved an operating income of 1.539 billion RMB, marking a 5.95% increase year-on-year [1] - The net profit attributable to the parent company was 267 million RMB, representing a year-on-year growth of 19.17% [1] - Basic earnings per share stood at 0.67 RMB [1] Market and Sales Strategy - The overall execution of orthopedic bulk procurement remained stable, with leading domestic brands increasing their market share [1] - The company actively adjusted its sales model and organizational structure, establishing a profit center system centered around professional departments to enhance marketing efficiency [1] - Product lines were further segmented, allowing for improved management and specialization within the sales team, leading to more precise clinical services and academic leadership in the market [1] - Focus on key surgical procedures through multi-product line collaborative sales resulted in significant growth in core hospital business, alongside increased efforts in developing lower-tier markets and promoting innovative products [1]

Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase year-on-year [1] Financial Performance - The company achieved an operating income of 1.539 billion RMB, representing a 5.95% increase compared to the previous year [1] - The net profit attributable to the parent company's shareholders was 267 million RMB, showing a year-on-year growth of 19.17% [1] - Basic earnings per share were reported at 0.67 RMB [1] Market and Sales Strategy - The overall execution of orthopedic bulk procurement remained stable during the reporting period, with leading domestic brands increasing their market share [1] - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around professional departments to enhance marketing efficiency [1] - There is a further segmentation of product lines through detailed management by sales divisions, which aims to improve the professional capabilities and focus of the sales team for more precise clinical services and academic leadership [1] - The company is concentrating on key surgical procedures with multi-product line collaborative sales, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [1]

研发方面，公司保持持续稳定的研发投入，在骨科生物材料、智能化设备、微创化耗材等方面加大投 入，带动新一代骨科产品的创新发展；同时，持续推进骨科耗材原材料的国产化及研发工艺改进，逐步 实现提质降本。 生产运营方面，公司持续加强数字化建设，进行运营系统平台的搭建，大幅提高了供应链效率；通过精 细化管理，持续降本增效，带来公司净利润的快速增长。 报告期内，骨科带量采购总体执行平稳，国产头部品牌市场份额持续提升。 销售方面，公司积极进行销售模式和销售组织结构的调整，打造以专业科室为核心维度的事业部利润中 心制，推动营销架构优化升级，激发销售组织活力；进一步细分产品线，通过销售事业部细分管理，提 高销售队伍的专业能力和聚焦度，更精准的进行临床服务和市场学术引领；通过聚焦关键术式的多产线 协同销售，核心重点医院业务增量明显，同时加大下沉市场的开发以及创新产品的推广，整体手术量持 续增长，带来收入和销量的持续增长。 格隆汇2月27日丨威高骨科(688161.SH)公布2025年度业绩快报，报告期内，公司营业收入15.39亿元，较 上年同期增长5.95%；实现归属于母公司所有者的净利润2.67亿元，较上年同期增长19.17% ...

格隆汇2月27日丨威高骨科(688161.SH)公布2025年度业绩快报，报告期内，公司营业收入15.39亿元，较 上年同期增长5.95%；实现归属于母公司所有者的净利润2.67亿元，较上年同期增长19.17%；实现归属 于母公司所有者的扣除非经常性损益的净利润2.52亿元，同比增长19.59%。报告期内，公司实施2025年 限制性股票激励计划，产生股份支付费用约2900万元，剔除股份支付费用影响，归属于母公司所有者的 净利润约2.96亿元，同比增长约32.13%；归属于母公司所有者的扣除非经常性损益的净利润约2.81亿 元，同比增长约33.34%。 影响经营业绩的主要原因： 报告期内，骨科带量采购总体执行平稳，国产头部品牌市场份额持续提升。 销售方面，公司积极进行销售模式和销售组织结构的调整，打造以专业科室为核心维度的事业部利润中 心制，推动营销架构优化升级，激发销售组织活力；进一步细分产品线，通过销售事业部细分管理，提 高销售队伍的专业能力和聚焦度，更精准的进行临床服务和市场学术引领；通过聚焦关键术式的多产线 协同销售，核心重点医院业务增量明显，同时加大下沉市场的开发以及创新产品的推广，整体手术量持 续增 ...

山东威高骨科材料股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688161 证券简称：威高骨科 公告编号：2026-005 | 归属于母公司的所 | 414,357.79 | 395,351.99 | 4.81 | | --- | --- | --- | --- | | 有者权益 | | | | | 股 本 | 40,000.00 | 40,000.00 | - | | 归属于母公司所有 | | | | | 者的每股净资产 | 10.36 | 9.88 | 4.81 | | （元） | | | | 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司 2025 年年度的定期报告为准。 3.数据若有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期内公司的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况 本公告所载山东威高骨科材料股份有限公司（以下简称"公司"）2025年度 主要财务数 ...